Clinical Trial Update: A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study [Phase 1]

View source ↗

Summary

Phase 1 RADIODOSE study assessing radiation dosimetry, safety, and tolerability of extended Lutetium-177 Vipivotide Tetraxetan in chemo-naïve adults with metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium-177 Vipivotide Tetraxetan (lutetium-177 vipivotide tetraxetan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Status: RECRUITING